WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Under the agreement, WuXi PharmaTech will become a provider of toxicologyand other non-clinical services to JANSSEN. In addition, JANSSEN will providetraining and other services, reimbursed by WuXi, to establish the GLP qualitysystem and technical capabilities to meet the international standards atWuXi's toxicology facility in Suzhou, China.
Construction of this facility, the largest in China with 314,000 squarefeet of space, was completed at the end of 2008. In 2009, the company hired amanagement team with extensive international experience and made substantialprogress in training an initial staff of technicians to perform GLP services.The facility is currently conducting non-GLP toxicology services, as well asclient-sponsored GLP validation studies to demonstrate our growingcapabilities. The company remains on target to begin offering GLP toxicologystudies by mid-2010.
Commenting on the agreement, Dr. Ge Li, Chairman and Chief ExecutiveOfficer of WuXi PharmaTech, said, "We are pleased to establish this newpartnership with JANSSEN, which builds on our existing agreement to providethem with integrated pharmaceutical R&D services. We believe that China, withits high-quality scientific talent and favorable cost structure, is destinedto become a major center for toxicology services over the next decade. We aimto become a leading provider of these services and to add toxicology to WuXi'sbroad, integrated platform of laboratory and preclinical services."For more information, please contact: Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-201-585-2048 Email: firstname.lastname@example.org Stephanie Liu (for the media) WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4362 Email: email@example.com
SOURCE WuXi PharmaTech (Cayman) Inc.
You May Also Like